A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
New publication alert: Engineered islets are making insulin and avoiding immune detection in first person treated
Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.
ADA 2025 Recap: Cures
Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type…
Accelerating cures: Four new grants from the Breakthrough T1D x Stem Cell Network Partnership
Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network (SCN) have partnered to support cell therapy research in Canada.
Making cures a reality: Clinical adoption of cell therapies
The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.
Breakthrough T1D helps organize an event at the European Parliament about unmet needs for T1D and accelerating cures
This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D…
Son’s love inspires new name for Breakthrough T1D Center of Excellence in New England
The Center has been renamed The Breakthrough T1D Barbara Dewey Cammett Center of Excellence in New England.
Medical Affairs team kicks off international islet cell therapy workshops at Breakthrough T1D HQ
Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.
Cell therapies in clinical trials: Moving the needle forward
Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how…
Challenges and solutions: The present and future of cell therapies for T1D
Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to…
